-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1773 Patients with AL Amyloidosis and Low Free Light Chain Burden Have Distinct Clinical Features and Outcome

Myeloma: Biology and Pathophysiology, excluding Therapy
Program: Oral and Poster Abstracts
Session: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Poster I
Saturday, December 5, 2015, 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

Paolo Milani, MD*, Andrea Foli, MD*, Marco Basset, MD*, Giovanni Palladini, MD, PhD and Giampaolo Merlini, MD

Amyloidosis Research and Treatment Center, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Background: In AL amyloidosis, circulating free light chains (FLC) are not only a clonal marker, but they are the causal agent of the disease. The recently validated criteria of hematologic response are based solely on the measurement of FLC. Patients with a difference between involved and uninvolved FLC (dFLC) <50 mg/L do not have measurable disease and cannot be assessed for response. Hence, they are commonly excluded from clinical trials. Nevertheless, these subjects represent a significant proportion of the patients suffering from AL amyloidosis, and given the lower burden of the toxic amyloidogenic precursor we hypothesize that they have distinctive clinical features.

Patients and methods: The study population is composed of 984 consecutive, newly diagnosed patients with AL amyloidosis evaluated between 2004 and 2013 at the Pavia Amyloidosis Center and prospectively followed for response and survival. We compared the 187 subjects (19%) who had a baseline dFLC <50 mg/L (low-dFLC group) with the remaining 797 patients (evaluable-dFLC group).

Results: Patients' characteristics are reported in the table. Heart involvement was less common in the low-dFLC group, and cardiac and renal dysfunction was more advanced in the evaluable-dFLC group, whereas renal involvement was more frequent and severe in the low-dFLC group. The Mayo clinic staging system based on NT-proBNP and cardiac troponin was able to discriminate three groups with significantly different outcomes in both groups (P<0.001). Overall survival was significantly better in the low-dFLC group (median 90 vs. 48 months, P<0.001). Within each Mayo stage patients with low-dFLC had a longer survival (at 3 years, 88% vs. 78%, P=0.03 in stage I, 69% vs. 45%, P=0.001 in stage II, 36% vs. 22%, P=0.02 in stage III). Complete response was associated with a significant survival advantage in the low-dFLC group (median 122 months vs. 92 months, P=0.02).

Conclusions: Nineteen percent of newly diagnosed patients with AL amyloidosis have very low dFLC burden. They represent a subgroup with a distinct and better outcome compared to other patients. Nevertheless, complete response can still significantly improve survival. Patients with low baseline dFLC can be included in clinical trials with appropriate stratification and are evaluable for complete response. 

Table. Patients' characteristics.

 

Variable

Low dFLC group

187 patients

N (%) - median (range)

Evaluable dFLC group

797 patients

N (%) - median (range)

P

Age, years

66 (40-85)

65 (30-87)

0.124

Male sex

99 (52)

444 (55)

0.272

Organ involvement

Heart

Kidney

Liver

>2 organs

88 (47)

142 (76)

26 (13)

99 (53)

662 (83)

511 (64)

112 (14)

566 (71)

<0.001

0.001

0.532

<0.001

Mayo Stage

1

2

3

69 (37)

91 (49)

27 (14)

109 (12)

 338  (42)

350 (44)

<0.001

0.071

<0.001

NYHA class 3

36 (19)

331 (40)

<0.001

NT-proBNP >8500 ng/L

12 (6)

212 (27)

0.0001

Renal Stage

1

2

3

62 (33)

85 (45)

40 (21)

384 (48)

320 (40)

93 (11)

0.001

0.107

0.001

Alkaline phosphatase, U/L

144 (82-215)

159 (99-239)

0.077

Involved ligh-chain type

κ

λ

37 (20)

 150 (80)

190 (24)

607 (76)

0.02

0.13

Bone marrow plasma cells, %

8 (5-12)

12 (8-20)

0.001

Melphalan-dexamethasone (MDex)

Cyclophosphamide-bortezomib-Dex

Bortezomib-MDex

Others

67 (35)

41 (22)

19 (10)

60 (33)

289 (36)

207 (26)

102 (12)

199 (26)

0.491

0.145

0.194

0.030

 

Disclosures: Merlini: Millennium-Takeda: Honoraria ; Janssen-Cilag: Honoraria ; Pfizer: Honoraria ; Prothena: Honoraria .

*signifies non-member of ASH